Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study.

Viking Therapeutics (NASDAQ: VKTX) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Viking Therapeutics seems to be doubling down on its hopes of making waves in the weight management market as a stand-alone ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for some time ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) has been given a consensus rating of “Buy” by the thirteen research ...

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

Viking Therapeutics (VKTX) announced the completion of subject enrollment in its Phase 2 clinical trial of the oral tablet formulation of ...

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy of the oral formulation ...

Viking announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. Read why I remain bullish on VKTX stock.

On Tuesday, H.C. Wainwright reaffirmed its Buy rating on Viking Therapeutics (NASDAQ:VKTX), with a steady price target of $102.00.... ByInvesting.com • Mar 11, 2025 CordenPharma and Viking ...

Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Viking Therapeutics, Inc. (VKTX).

Viking has found a manufacturing partner, removing a key overhang on the stock Viking Therapeutics Inc.'s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a ...